The Week in Review: February 9 – February 16, 2018

Friday, February 16, 2018 News Recap: HCV & Heart Disease: Evolving Recognition of Chronic Hepatitis C Infection as a Modifiable Risk Factor for CVD. This article examines the evidence for clinical and subclinical cardiovascular diseases in chronic hepatitis c infection, as well as the effect of treatment on cardiovascular outcomes. News from Around the World: NZ: Thousands of Hepatitis C sufferers unaware a cure is within reach. A Hepatitis...

Study reveals the liver’s ‘weak spot’ for hepatitis B virus replication

In a surprising discovery, researchers from the Singapore Immunology Network (SIgN), A*STAR, have found that the liver is the main site of hepatitis B (HBV) replication—not only because it contains material that helps the virus proliferate, but also because most other tissues of the body contain proteins that actively repress HBV replication. "We've been working on this project for a number of years because HBV is very prevalent in Asia," says Ee Chee Ren

The Week in Review: February 2 – February 9, 2018

Friday, February 9, 2018 News Recap: Epidemiology: CTAC Launches Campaign to End Hepatitis C in Canada. The Canadian Treatment Action Council (CTAC) has published a white paper entitled, "The time has come to eliminate hepatitis C in Canada," which summarizes the increasing gaps in Canada's response to the hepatitis C epidemic and identifies seven calls-to-action. #EASLmono: Expanding the conversation on hepatitis elimination. The recent European...

7 recent reports on HBV treatment approvals, efficacy

Direct-acting antivirals have provided a highly viable cure for hepatitis C, but hepatitis B remains a complicated infectious disease and requires lengthy treatment and management in chronic cases. While HBV is vaccine-preventable, individuals who do contract HBV must be aware of its progression as it can lead to severe liver-related complications such as acute liver failure and may require liver transplantation. The following reports provide recent findi

The Week in Review: December 1 – December 8, 2017

Friday, December 8, 2017 News Recap: URGENT BC Patient and Caregiver Input Request: Vosevi. We need to hear your voice! Patient and Caregiver input is requested by BC PharmaCare on Gilead’s combo of sofosbuvir, velpatasvir, and voxilaprevir (SOF-VEL-VOX or Vosevi™) for Genotypes 1-6. Personal Stories This week we have two great stories of triumphing over HepC: Aidain’s ‘I will never forget the day I found out I had hepatitis c’, and Patric...

Elevated Levels of HBV DNA and HBsAg May Increase Liver Cancer Risk

HealthDay News — Elevated levels of hepatitis B virus (HBV) DNA and hepatitis B surface antigen (HBsAg) are associated with increased risks of liver cancer, according to a study published in the Journal of Gastroenterology and Hepatology. The researchers found that the risk of liver cancer was positively associated with increasing levels of HBV DNA and HBsAg in dose-response manners.The adjusted odds ratios [ORs] increased from 2.11 to 10.47  for those wi

Benitec and Biotron in the race for $3.5b Hepatitis B market

Chronic Hepatitis B, a currently incurable disease, is attracting growing attention among international biotechs. The World Health Organisation estimates 257 million people live with Hep B and up to 900,000 die each year from related diseases such as liver cancer and cirrhosis. In Australia, more than 232,000 people have chronic hepatitis B, according to lobby group Hepatitis Australia. “Deaths from primary liver cancer have been climbing faster tha

The Week in Review: September 29 – October 6, 2017

Friday, October 6, 2017 News Recap: Liver Cancer Two studies on liver cancer in the news last week highlighted the global prevalence and causes of this terrible disease.  The first showed a direct correlation between excess weight and cancer occurrence (including liver cancer) – Cancers linked to excess weight make up 40% of all US diagnoses, study finds, while the second focussed on the global incidence of primary liver cancer. Hepatitis B virus wa...

Reactivation Rate of Hepatitis B in Inflammatory Arthritis Tx With DMARDs

It's not only DAAs than can reactivate HBV. In patients with inflammatory arthritis receiving disease-modifying antirheumatic drugs (DMARDs), rates of hepatitis B (HBV) reactivation differ between those whose disease is resolved and those with chronic HBV infection. Findings from the systematic review and meta-analysis were published in Arthritis Care & Research (Hoboken). Patients with chronic HBV generally have a 5-fold to 8-fold higher risk for HBV

The Week in Review: August 18 – August 25, 2017

Friday, August 25, 2017 News Recap: Public health issues Hep B risk warning: Tools used in procedures such as callus scraping and cutting toenails could become contaminated with the virus and remain contaminated because of the sterilization practices followed. Public health authorities in Owen Sound have identified a local foot care clinic as a potential source of hepatitis B and are warning patients – other than orthotics patients – to consult a doc...